US4853227A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Transdermal administration of a systemic active agent to a premature neonatal infant
Assignee: Novartis Corp
•
Filing: 1987-10-23
•
Granted: 1989-08-01
•
Expires: 2007-10-23
Abstract
Abstract A method of treating a premature neonatal infant of a gestational age between about 24 and about 35 weeks with a pharmaceutically acceptable, systemically active, substantially skin compatible, water-soluble neonatal therapeutic agent having a molecular weight below about 5000, and which agent is substantially non-transmissable through normal mature intact human skin, comprising: (a) applying to the intact neonatal skin of said infant a transdermal device comprising (i) a backing member, (ii) a substantially shape retaining hydrogel reservoir having a water content of between about 5 percent and about 95 percent preferably between 10 percent and 80 percent by weight of said reservoir and containing an effective amount of said agent, (iii) a skin contacting surface of predetermined area, and (iv) means for maintaining said reservoir in material transmitting relationship to said skin; (b) maintaining said skin contacting surface of said device in material transmitting relationship to said intact neonatal skin of the infant for an extended period of time; and (c) delivering said agent through the intact neonatal skin in a controlled continuous manner such that the blood plasma level of said agent is substantially within the therapeutic index of said agent for a majority of said extended period of time.
Inventors
- 👤 Tamie Kurihara-Bergstrom
- 👤 William R. Good
- 👤 Charles D. Ebert
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 18:15
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/70; A61K9/7023
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
232 words
A method of treating a premature neonatal infant of a gestational age between about 24 and about 36 weeks with a pharmaceutically acceptable, systemically active, substantially skin compatible, water-soluble neonatal therapeutic agent having molecular weight below about 5000, and which agent is substantially non-transmissable through normal mature full term infant intact human skin, comprising: (a) applying to the intact neonatal skin of said infant of gestational age between about 24 and about 36 weeks a transdermal device comprising (i) a backing member, (ii) a substantially shape retaining hydrogel reservoir having a water content of between about 5 percent and about 95 percent preferably between 10 percent and 80 percent by weight of said reservoir and containing an effective amount of said agent which is substantially non-transmissable through normal mature intact human skin, (iii) a skin contacting surface of predetermined area, and (iv) means for maintaining said reservoir in material transmitting relationship to said skin; (b) maintaining said skin contacting surface of said device in material transmitting relationship to said intact neonatal skin of the infant for an extend period of time; and (c) delivering said agent through the intact neonatal skin in a controlled continuous manner such that the blood plasma level of said agent is substantially within the therapeutic index of said agent is substantially within the therapeutic index of said agent for a majority of said extended period of time.
Claim 2
Independent Claim
232 words
A method of treating a premature neonatal infant of a gestational age between about 24 and about 36 weeks with a pharmaceutically acceptable, systemically active, substantially skin compatible, water-soluble neonatal therapeutic agent having molecular weight below about 5000, and which agent is substantially non-transmissable through normal mature full term infant intact human skin, comprising: (a) applying to the intact neonatal skin of said infant of gestational age between about 24 and about 36 weeks a transdermal device comprising (i) a backing member, (ii) a substantially shape retaining hydrogel reservoir having a water content of between about 5 percent and about 95 percent preferably between 10 percent and 80 percent by weight of said reservoir and containing an effective amount of said agent which is substantially non-transmissable through normal mature intact human skin, (iii) a skin contacting surface of predetermined area, and (iv) means for maintaining said reservoir in material transmitting relationship to said skin; (b) maintaining said skin contacting surface of said device in material transmitting relationship to said intact neonatal skin of the infant for an extend period of time; and (c) delivering said agent through the intact neonatal skin in a controlled continuous manner such that the blood plasma level of said agent is substantially within the therapeutic index of said agent is substantially within the therapeutic index of said agent for a majority of said extended period of time.
Claim 3
Dependent Claim
14 words
A method according to claim 1, wherein the hydrogel is a crosslinked hydrophilic polymer.
Claim 4
Dependent Claim
27 words
A method according to claim 1, wherein the hydrogel contains between about 10 percent and about 80 percent water by weight, based upon the weight of hydrogel.
Claim 5
Dependent Claim
16 words
A method according to claim 1, wherein said backing member is substantially impermeable to the reservoir.
Claim 6
Dependent Claim
25 words
A method according to claim 1, wherein the skin contacting surface area of the device is between about 0.5 and about 20 cm 2 .
Claim 7
Dependent Claim
21 words
A method according to claim 1, wherein said extended period of time is between about 12 hours and about 10 days.
Claim 8
Dependent Claim
39 words
A method according to claim 1, wherein said water soluble neonatal therapeutic agent is selected from the group consisting of an antibiotic, a cardiovascular, respiratory or metabolic agent, a vitamin, an anticoagulant, an anticonvulsant, an antidote or a diuretic.
Claim 9
Dependent Claim
17 words
A method according to claim 7, wherein said agent is a water-soluble pharmaceutically acceptable salt of theophylline.
Claim 10
Dependent Claim
12 words
A method according to claim 8, wherein said agent is choline theophylline.
References Cited (Backward Citations)
US27401A
Cited
US3520949A
Cited
USRE27401E
Cited
US4177056A
Cited
US4588580A
Cited
US4588580B1
Cited
US4588580B2
Cited
US4568343A
Cited
US4668506A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-07-31 | 1993-01-30 | 1993-08-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-07-31 | 1997-01-30 | 1997-08-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-07-31 | 2001-01-30 | 2001-08-01 | $7700.00 | Window Closed / Lapsed |